In this case, the plaintiff went into the hospital for a hysterectomy and a bilateral salpingectomy - one of the most common treatments for fibroids. Historically, such a procedure at one time involved invasive surgery. However, as modern medicine has moved to less-invasive techniques that require less healing time and an equally smaller draw on hospital resources, power morcellation was soon embraced as a preferred method of treatment.
This is no longer a preferred option, given the havoc power morcellation can wreak, with an impact to health far more devastating than merely a longer convalescence.
The plaintiff in question underwent the hysterectomy and a bilateral salpingectomy by way of power morcellation. It should be noted that prior to the power morcellation procedure, the plaintiff was cancer free.
That wasn’t the case following her treatment. Post-surgery, the patient was diagnosed with stage-4 cancer that subsequently spread into her bones and breasts.
In her laparoscopic power morcellation hysterectomy lawsuit, the plaintiff asserts that the process of morcellation to shred the fibrous tissue for subsequent removal freed previously undetected cancer cells encapsulated with the uterine fibroids, spreading cancer throughout her body.
READ MORE LAPAROSCOPIC POWER MORCELLATION LEGAL NEWS
Ethicon, a division of Johnson & Johnson, pulled its power morcellator from the market. However, other manufacturers have yet to follow suit.
The US Food and Drug Administration (FDA) has since determined that power morcellation is no longer the preferred method by which to remove fibroids and has suggested its use is among dangerous medical procedures best avoided.
The power morcellation case referenced here is against Karl Storz Endovision Inc., the manufacturer of the particular power morcellator used in the procedure. The lawsuit, bearing Case No. 2:15-cv-10352-TGB-APP, was filed January 26 of last year in the US District Court for the Eastern Division of Michigan.